Sobr Safe, Inc. (SOBR) Stock Price & Analysis
Sobr Safe, Inc. (SOBR) fell 11.96% to USD 0.75 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
SOBR last closed at USD 0.85; the session ranged USD 0.75–0.85 on volume of 112,827 shares. Market capitalization is $2.09M, with a 52-week range of USD 0.48–5.29 (NCM). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 0.75 |
|---|---|
| Change | ▼ 11.96% (down) |
| Previous Close | USD 0.85 |
| Open | USD 0.85 |
| Day Range | USD 0.75 – 0.85 |
| 52-Week Range | USD 0.48 – 5.29 |
| Volume | 112,827 shares |
| Market Cap | $2.09M |
| Exchange | NCM |
Technical Analysis (SOBR)
Nexqual's technical model rates SOBR "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.11 (neutral) |
| vs SMA50 | Below (USD 0.95) |
| MACD | -0.04 (negative) |
Analyst Ratings (SOBR)
Wall Street analysts rate SOBR "None", per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | None |
|---|
Earnings (SOBR)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -132 vs est -110 ▼ miss |
| 2023-06-30 | USD -170.61 vs est -154 ▼ miss |
| 2023-03-31 | USD -152.9 vs est -198 ▲ beat |
| 2022-12-31 | USD -88 vs est -220 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financials & Fundamentals (SOBR)
| Total Revenue | $429,807 |
|---|---|
| Revenue Growth (YoY) | -8.80% |
| Gross Margin | +53.39% |
| Operating Margin | -2923.95% |
| Profit Margin | +0.00% |
| ROE | -131.91% |
| Debt / Equity | 3.79 |
| Current Ratio | 2.18 |
| Total Cash | $2.12M |
| Total Debt | $100,149 |
| Free Cash Flow | $-4.84M |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (SOBR)
Nexqual rates Sobr Safe, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Weak — Revenue -9% YoY (latest Q), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $2M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -132%, ROA -68.7% |
Ownership (SOBR)
| Insider Ownership | +19.95% |
|---|---|
| Institutional Ownership | +9.82% |
| Shares Outstanding | 2.81M |
| Float | 2.29M |
| Short % of Float | +9.95% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Leadership (SOBR)
Sobr Safe, Inc. is led by David J. Gandini (age 67), Chairman, Secretary & CEO, per Nexqual as of June 10, 2026 at 02:23 UTC.
| Chairman, Secretary & CEO | David J. Gandini (age 67) |
|---|---|
| CFO, Treasurer and Executive VP of Business Operations & Marketing | Christopher Whitaker (age 53) |
Major Backers & Investors (SOBR)
Notable institutional backers of Sobr Safe, Inc. include Fidelity, HRT Financial LP, Ashton Thomas Private Wealth, LLC, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.77% |
| HRT Financial LP | 1.25% |
| Ashton Thomas Private Wealth, LLC | 0.43% |
| Tower Research Capital LLC (TRC) | 0.22% |
| UBS Group AG | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.8% |
| Vanguard Group | 0.74% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
From Sobr Safe, Inc.'s Latest SEC 10-K Filing (filed 2026-04-10)
Key Strengths & Strategy (as disclosed to the SEC)
- To protect our proprietary rights, we will rely on a combination of patent, copyright and trade secret laws, confidentiality agreements with our employees and third parties, and protective contractual provisions.
- Our ongoing focus will be placed on product innovation, providing data-driven user insights, and ensuring that new offerings remain consistent with our mission to promote a healthier, safer world free from the impacts of alcohol with balanced lifestyles.   Marketing   We have developed a marketing plan that includes:     Our marketing strategy continues to evolve as we expand our focus across business-to-business (B2B) and consumer markets.
- If our technology proves to be ineffective at tracking alcohol in an individual's system through perspiration from their skin, it would significantly impact our business.   We may not be able to meet our future capital needs.   To date, we have generated limited revenue.
- Any financing, if available, may be on unfavorable terms.   If we cannot obtain, achieve or sustain profitability or additional funding, our technology, product development and commercialization efforts may be reduced or discontinued, and we may not be able to continue operations.   We have experienced recurring net losses since inception, and as of December 31, 2025, had an accumulated deficit of $106,873,875.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRAX | Virax Biolabs Group Limited | USD 0.19 | ▼ 11.64% |
| AKAN | Akanda Corp. | USD 13.76 | ▼ 11.96% |
| LUCY | Innovative Eyewear, Inc. | USD 0.9 | ▼ 0.85% |
| SKYA | SkyAI, Inc. | USD 1.16 | ▼ 4.13% |
| XPON | Expion360 Inc. | USD 0.45 | ▼ 6.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.